Suppr超能文献

具有降低的脱靶的蛋白水解靶向嵌合体。

Proteolysis-targeting chimeras with reduced off-targets.

机构信息

Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Department of Medicine, Harvard Medical School, Boston, MA, USA.

出版信息

Nat Chem. 2024 Feb;16(2):218-228. doi: 10.1038/s41557-023-01379-8. Epub 2023 Dec 18.

Abstract

Proteolysis-targeting chimeras (PROTACs) are molecules that induce proximity between target proteins and E3 ligases triggering target protein degradation. Pomalidomide, a widely used E3 ligase recruiter in PROTACs, can independently degrade other proteins, including zinc-finger (ZF) proteins, with vital roles in health and disease. This off-target degradation hampers the therapeutic applicability of pomalidomide-based PROTACs, requiring development of PROTAC design rules that minimize off-target degradation. Here we developed a high-throughput platform that interrogates off-target degradation and found that reported pomalidomide-based PROTACs induce degradation of several ZF proteins. We generated a library of pomalidomide analogues to understand how functionalizing different positions of the phthalimide ring, hydrogen bonding, and steric and hydrophobic effects impact ZF protein degradation. Modifications of appropriate size on the C5 position reduced off-target ZF degradation, which we validated through target engagement and proteomics studies. By applying these design principles, we developed anaplastic lymphoma kinase oncoprotein-targeting PROTACs with enhanced potency and minimal off-target degradation.

摘要

蛋白水解靶向嵌合体(PROTACs)是一种能诱导靶蛋白与 E3 连接酶接近的分子,从而触发靶蛋白降解。来那度胺是 PROTAC 中广泛应用的 E3 连接酶招募物,它可以独立降解其他蛋白质,包括锌指(ZF)蛋白,这些蛋白在健康和疾病中起着重要作用。这种非靶降解会阻碍基于来那度胺的 PROTAC 的治疗应用,需要开发 PROTAC 设计规则来最小化非靶降解。在这里,我们开发了一种高通量平台来检测非靶降解,发现报道的基于来那度胺的 PROTAC 会诱导几种 ZF 蛋白的降解。我们生成了来那度胺类似物文库,以了解在邻苯二甲酰亚胺环的不同位置、氢键、立体和疏水性效应对 ZF 蛋白降解的影响。在 C5 位置进行适当大小的修饰可以减少非靶 ZF 降解,我们通过靶标结合和蛋白质组学研究验证了这一点。通过应用这些设计原则,我们开发了针对间变性淋巴瘤激酶癌蛋白的 PROTAC,其具有增强的效力和最小的非靶降解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d1b/10913580/c0d550559982/nihms-1970808-f0008.jpg

相似文献

1
Proteolysis-targeting chimeras with reduced off-targets.具有降低的脱靶的蛋白水解靶向嵌合体。
Nat Chem. 2024 Feb;16(2):218-228. doi: 10.1038/s41557-023-01379-8. Epub 2023 Dec 18.
6
Homo-PROTACs for the Chemical Knockdown of Cereblon.用于 Cereblon 化学敲低的同型 PROTACs
ACS Chem Biol. 2018 Sep 21;13(9):2771-2782. doi: 10.1021/acschembio.8b00693. Epub 2018 Sep 5.
7
Light-induced control of protein destruction by opto-PROTAC.光诱导的光控 PROTAC 蛋白降解
Sci Adv. 2020 Feb 21;6(8):eaay5154. doi: 10.1126/sciadv.aay5154. eCollection 2020 Feb.

引用本文的文献

1
FDA-approved kinase inhibitors in PROTAC design, development and synthesis.FDA批准的用于PROTAC设计、开发和合成的激酶抑制剂。
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2542357. doi: 10.1080/14756366.2025.2542357. Epub 2025 Aug 12.
6
Characterization of a dual degrader of MDM2 and GSPT1.MDM2和GSPT1双重降解剂的表征
Eur J Med Chem. 2025 Oct 5;295:117793. doi: 10.1016/j.ejmech.2025.117793. Epub 2025 May 21.
7
Targeted protein degradation for cancer therapy.用于癌症治疗的靶向蛋白质降解
Nat Rev Cancer. 2025 Apr 25. doi: 10.1038/s41568-025-00817-8.
9
Targeted degradation of CDK9 potently disrupts the MYC-regulated network.CDK9的靶向降解有力地破坏了MYC调控的网络。
Cell Chem Biol. 2025 Apr 17;32(4):542-555.e10. doi: 10.1016/j.chembiol.2025.03.001. Epub 2025 Mar 27.

本文引用的文献

4
Targeted protein degraders crowd into the clinic.靶向蛋白降解剂纷纷涌入临床。
Nat Rev Drug Discov. 2021 Apr;20(4):247-250. doi: 10.1038/d41573-021-00052-4.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验